BERKELEY, Calif., and VANCOUVER, British Columbia, February 12, 2019 – BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) ...
· Completed development of a novel frozen formulation of Bria-IMT™ for on-demand shipment to clinical ...
· Interim data indicate an excellent safety profile for the combination regimen in advanced breast ...
Note: This Press Release contains amendments to the press release previously issued on Nov. 19, ...
· Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and ...
Phoenix, Nov. 6, 2018 (GLOBE NEWSWIRE) – BriaCell Therapeutics Corp. (“BriaCell,” the “Company”) (TSX-V: BCT) ...
· Patient dosing is underway in a combination study of Bria-IMT™ with KEYTRUDA® (by Merck ...
· BriaCell has achieved positive proof of concept in the Phase IIa study of Bria-IMT™ ...
NEW YORK (Sept 25, 2018) – via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution ...
– Scientific findings will discuss circulating tumor cells as a biomarker of tumor response, which ...
Accessibility Tools